Precipio, Inc. PRPO 深 滬
已收盤 02-06 16:00:00 美东时间
20.06
-0.310
-1.52%
華盛通- 最 高21.87
- 今 開21.87
- 成交量 9056股
- 最 低 20.00
- 昨 收 20.37
- 總市值 3514.53万
- 52周最高 28.50
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 3.90
- 委 比 98.41%
- 總股本 175.20万
- 歷史最高 8448.00
- 量 比 0.69
- 振 幅 9.18%
- 歷史最低 3.90
- 每 手 1
- 風險率 6.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Precipio Takes Major Steps Toward a Clean Balance Sheet
Specialty cancer diagnostics company Precipio, Inc. has cleaned up its balance sheet with two major achievements: repaying a $1.1 million advance from Change Healthcare and exercising all financial warrants. The company now only holds a minor $80,000 loan and 10,000 warrants for vendors. CEO Ilan Danieli highlights reduced financial risk and ongoing efforts to grow the business and create shareholder value.
01-15 14:00
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Precipio, Inc. will present findings from a joint study with Memorial Sloan Kettering Cancer Center at the ASH Meeting. The study, evaluating Precipio’s BCR::ABL1 assay, analyzed 895 patient samples and demonstrated superior performance compared to other leading platforms, positively impacting patient care and improving laboratory workflows. The presentation will occur on December 8th in Orlando, Florida. Precipio is a cancer diagnostics company ...
2025-12-05 15:00
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
Precipio, Inc. reported a limited unauthorized access to a specific data folder in its secure cloud environment, which did not impact operations, patient care, or financial data. The company promptly responded by securing systems, resetting passwords, and engaging cybersecurity experts. The accessed files contained historical operational information with no sensitive patient or financial data. Precipio's systems remain stable, and the incident is...
2025-12-04 13:00
Precipio Announces its Q3-2025 Financial Results
Precipio, Inc. reported Q3-2025 financial results, with revenues reaching $6.8M, a 30% YoY increase and 20% QoQ growth. Adjusted EBITDA was $469K, up $369K YoY and $500K QoQ, turning positive. Cash flow improved by $433K QoQ, from a burn of ($148K) to $285K generated. Pathology Services Division revenue rose 20% QoQ, while Products Division grew 16% QoQ. CEO Ilan Danieli highlighted operational efficiencies and financial discipline driving positi...
2025-11-14 21:30
Precipio Announces Q3-2025 Shareholder Update Call
Precipio, Inc., a specialty cancer diagnostics company, will host its Q3-2025 corporate update conference call on November 17, 2025, at 5:00 PM ET. Participants can join by dialing 800-717-1738 and requesting the Precipio conference call. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available on Precipio's website. The company focuses on improving cancer diagnostics to reduce misdiagnoses, enhance ...
2025-11-04 22:00
Precipio Terminates Its ATM
Specialty cancer diagnostics company Precipio, Inc. has terminated its At-The-Market (ATM) instrument with investment bank Alliance Global Partners (AGP). CEO Ilan Danieli stated that the company is in a stronger financial position now, with positive cash flow and increased cash reserves, making the ATM tool unnecessary for capital raises. This move reflects management's commitment to responsible capital management and creating shareholder value.
2025-09-02 14:00
Precipio Unveils Advancements in AML Diagnostic Technology
The latest announcement is out from Precipio ( ($PRPO) ). On August 18, 2025, P...
2025-08-19 05:32
Precipio Q2 EPS $0.05 Up From $(0.83) YoY, Sales $5.654M Up From $4.441M YoY
Precipio (NASDAQ:PRPO) reported quarterly earnings of $0.05 per share. This is a 106.02 percent increase over losses of $(0.83) per share from the same period last year. The company reported $5.654 million in sales this
2025-08-14 05:05
Precipio Announces its Q2-2025 Financial Results
<p>Precipio Inc., a specialty cancer diagnostics company, reported Q2-2025 financial results with $5.7M in revenue, a 27% YoY and 15% QoQ increase. Adjusted EBITDA improved to $(78K) from $(609K) YoY. Cash flow used decreased 71% YoY. Both product and pathology services divisions showed strong growth, with gross margins improving to 43% overall. The company expects to end the year debt-free and cash flow positive. A conference call is scheduled f...
2025-08-13 21:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
2025-07-14 20:08
